These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 9748138)

  • 1. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
    Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
    Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
    Zhigang Z; Wenlu S
    Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
    Arai T; Fujita K; Fujime M; Irimura T
    Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
    Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
    J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z; Wenlv S
    Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
    Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
    BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
    Fu Z; Kitagawa Y; Shen R; Shah R; Mehra R; Rhodes D; Keller PJ; Mizokami A; Dunn R; Chinnaiyan AM; Yao Z; Keller ET
    Prostate; 2006 Feb; 66(3):248-56. PubMed ID: 16175585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
    Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
    Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.
    Potters L; Purrazzella R; Brustein S; Fearn P; Leibel SA; Kattan MW
    Cancer; 2002 Oct; 95(7):1451-6. PubMed ID: 12237913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
    Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
    J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
    Puccetti L; Supuran CT; Fasolo PP; Conti E; Sebastiani G; Lacquaniti S; Mandras R; Milazzo MG; Dogliani N; De Giuli P; Fasolis G
    Eur Urol; 2005 Aug; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
    Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
    D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
    J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.